The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Elvina 0.03mg/3mg film-coated tablets

Gedeon Richter PlcPA1330/007/001

Main Information

Trade NameElvina 0.03mg/3mg film-coated tablets
Active SubstancesDrospirenone
Dosage FormFilm-coated tablet
Licence HolderGedeon Richter Plc
Licence NumberPA1330/007/001

Group Information

ATC CodeG03AA Progestogens and estrogens, fixed combinations
G03AA12 drospirenone and ethinylestradiol


License statusAuthorised
Licence Issued20/08/2010
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceWhile you are receiving this medication, you should see your doctor regularly at least every six to twelve months. If you have any unusual symptoms such as unexplained pains in the chest, abdomen or legs, you must consult your doctor immediately.
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available

Educational Materials - HCP

Educational Materials - Patient

« Back